These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 34897554)

  • 1. Prospects for Development of Induced Pluripotent Stem Cell-Derived CAR-Targeted Immunotherapies.
    Mazza R; Maher J
    Arch Immunol Ther Exp (Warsz); 2021 Dec; 70(1):2. PubMed ID: 34897554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IPSC-derived CAR-NK cells for cancer immunotherapy.
    Lin X; Sun Y; Dong X; Liu Z; Sugimura R; Xie G
    Biomed Pharmacother; 2023 Sep; 165():115123. PubMed ID: 37406511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.
    Lahimchi MR; Maroufi F; Maali A
    Cell Reprogram; 2023 Oct; 25(5):195-211. PubMed ID: 37782910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induced Pluripotent Stem Cells (iPSCs) Provide a Potentially Unlimited T Cell Source for CAR-T Cell Development and Off-the-Shelf Products.
    Sadeqi Nezhad M; Abdollahpour-Alitappeh M; Rezaei B; Yazdanifar M; Seifalian AM
    Pharm Res; 2021 Jun; 38(6):931-945. PubMed ID: 34114161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-clinical efficacy, safety and stable clinical cell processing of induced pluripotent stem cell-derived anti-glypican-3 chimeric antigen receptor-expressing natural killer/innate lymphoid cells.
    Ueda T; Kumagai A; Iriguchi S; Yasui Y; Miyasaka T; Nakagoshi K; Nakane K; Saito K; Takahashi M; Sasaki A; Yoshida S; Takasu N; Seno H; Uemura Y; Tamada K; Nakatsura T; Kaneko S
    Cancer Sci; 2020 May; 111(5):1478-1490. PubMed ID: 32133731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions.
    Zhang L; Tian L; Dai X; Yu H; Wang J; Lei A; Zhu M; Xu J; Zhao W; Zhu Y; Sun Z; Zhang H; Hu Y; Wang Y; Xu Y; Church GM; Huang H; Weng Q; Zhang J
    J Hematol Oncol; 2020 Nov; 13(1):153. PubMed ID: 33176869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Better by design: What to expect from novel CAR-engineered cell therapies?
    Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS
    Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3D-organoid culture supports differentiation of human CAR
    Wang Z; McWilliams-Koeppen HP; Reza H; Ostberg JR; Chen W; Wang X; Huynh C; Vyas V; Chang WC; Starr R; Wagner JR; Aguilar B; Yang X; Wu X; Wang J; Chen W; Koelker-Wolfe E; Seet CS; Montel-Hagen A; Crooks GM; Forman SJ; Brown CE
    Cell Stem Cell; 2022 Apr; 29(4):515-527.e8. PubMed ID: 35278370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Adoptive Cell Therapy Using Induced Pluripotent Stem Cell-Derived T Cells.
    Netsrithong R; Wattanapanitch M
    Front Immunol; 2021; 12():759558. PubMed ID: 34650571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Basic Research and Clinical Development of Regenerative Immunotherapy Using iPS Cells].
    Kanie K; Kaneko S
    Gan To Kagaku Ryoho; 2023 May; 50(5):571-576. PubMed ID: 37218314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
    Saetersmoen ML; Hammer Q; Valamehr B; Kaufman DS; Malmberg KJ
    Semin Immunopathol; 2019 Jan; 41(1):59-68. PubMed ID: 30361801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generating universal chimeric antigen receptor expressing cell products from induced pluripotent stem cells: beyond the autologous CAR-T cells.
    Deng X; Zhou J; Cao Y
    Chin Med J (Engl); 2023 Jan; 136(2):127-137. PubMed ID: 36806264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hematopoietic stem cell- and induced pluripotent stem cell-derived CAR-NK cells as reliable cell-based therapy solutions.
    Arias J; Yu J; Varshney M; Inzunza J; Nalvarte I
    Stem Cells Transl Med; 2021 Jul; 10(7):987-995. PubMed ID: 33634954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. iPSC-Derived Natural Killer Cell Therapies - Expansion and Targeting.
    Goldenson BH; Hor P; Kaufman DS
    Front Immunol; 2022; 13():841107. PubMed ID: 35185932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors.
    Ueda T; Kaneko S
    Int J Hematol; 2021 Nov; 114(5):572-579. PubMed ID: 32705572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Development of CAR-T cell therapy using allogeneic iPS cells].
    Kaneko S
    Rinsho Ketsueki; 2022; 63(10):1454-1460. PubMed ID: 36351655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells.
    Tang SY; Zha S; Du Z; Zeng J; Zhu D; Luo Y; Wang S
    Stem Cell Res Ther; 2021 Nov; 12(1):580. PubMed ID: 34802459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors.
    Sloas C; Gill S; Klichinsky M
    Front Immunol; 2021; 12():783305. PubMed ID: 34899748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoantigen Specific T Cells Derived From T Cell-Derived Induced Pluripotent Stem Cells for the Treatment of Hepatocellular Carcinoma: Potential and Challenges.
    Lu F; Ma XJ; Jin WL; Luo Y; Li X
    Front Immunol; 2021; 12():690565. PubMed ID: 34054880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.